Pfizer (PFE) net profit drops 59% to $2.57B from $6.32B a year earlier, which included a gain of $4.8B related to the divestiture of the company's nutrition operations.
Revenue breakdown: Primary Care -8%, Specialty Care -5%, established products +6%, Consumer Healthcare +2%, Oncology +29%.
Emerging markets revenues +9%.
Expects adjusted 2014 EPS of $2.20-2.30 vs consensus of $2.28, and adjusted revenues of $49.2-51.2B vs $49.74B and $51.58B in 2013.
Repurchased $4.6B of stock in Q4, $16.3B in FY.
Shares +2.8%. (PR)